(2008). A ‘GAG’ reflex prevents repair of the damaged CNS.
(1982). Biosynthesis of dermatan sulphate. Assay and properties of the uronosyl C-5 epimerase.
(1997). C1q augments platelet activation in response to aggregated Ig.
(1979). Characterization of the sulfated glycosaminoglycan on the surface and in the storage granules of rabbit platelets.
(1998). CLAMP: a biosensor kinetic data analysis program.
(2007). Complement activation in Lyme neuroborreliosis–increased levels of C1q and C3a in cerebrospinal fluid indicate complement activation in the CNS.
(2008). Complement activation triggered by chondroitin sulfate released by thrombin receptor-activated platelets.
Complement component C3 binds to activated normal platelets without preceding proteolytic activation and promotes binding to complement receptor
(2008). Contaminated heparin associated with adverse clinical events and activation of the contact system.
(1995). Effects of thrombin and the thrombin receptor activating peptide, SFLLRN, on redistribution of platelet alpha-granule contents are similar and independent of the extent of thromboxane formation.
(2006). Evidence that complement protein C1q interacts with C-reactive protein through its globular head region.
(2008). Factor H binds to platelet integrin alphaIIbbeta3.
(2005). Factor H binds to washed human platelets.
(1998). Functional characterization of a recombinant form of the C-terminal, globular head region of the B-chain of human serum complement protein, C1q.
(2006). Glycosaminoglycans and their proteoglycans: hostassociated molecular patterns for initiation and modulation of inflammation.
(1990). High affinity interaction between C4b-binding protein and vitamin K-dependent protein S in the presence of calcium. Suggestion of a third component in blood regulating the interaction.
(1987). Human blood platelets possess specific binding sites for C1q.
(1988). Identification and partial characterization of human platelet C1q binding sites.
(1999). Improving biosensor analysis.
(1995). Interpreting complex binding kinetics from optical biosensors: a comparison of analysis by linearization, the integrated rate equation, and numerical integration.
(1965). Isolation of Beta If-Globulin from Human Serum and Its Characterization as the Fifth Component of Complement.
(1981). Large scale isolation of functionally active components of the human complement system.
(1993). Larsson A
(2005). Mass spectrometry analysis of the oligomeric C1q protein reveals the B chain as the target of trypsin cleavage and interaction with fucoidan.
(2006). Metabolism and biochemical/physiological roles of chondroitin sulfates: analysis of endogenous and supplemental chondroitin sulfates in blood circulation.
(1991). Normal human serum depleted of C1q, factor D and properdin: its use in studies of complement activation.
(1992). Platelet interactions with C1q in whole blood and in the presence of immune complexes or aggregated IgG.
(1994). Platelet membrane receptors for the complement component C1q.
(1986). Purification and characterization of human platelet proteoglycan.
(1981). Purification and radiolabeling of human C1q.
(2003). Recent advances in the structural biology of chondroitin sulfate and dermatan sulfate.
(1987). Regulation of the activity of platelet-bound C3 convertase of the alternative pathway of complement by platelet factor H.
(2008). Serglycin proteoglycan deletion induces defects in platelet aggregation and thrombus formation in mice.
(2007). Structural determination of novel sulfated octasaccharides isolated from chondroitin sulfate of shark cartilage and their application for characterizing monoclonal antibody epitopes.
(2006). Structure of chondroitin sulfate.
(1972). Synthesis and localization of sulphated mucopolysaccharide in megakaryocytes and platelets of the rat, an anlysis by electronmicroscope autoradiography.
(1994). The kinetics of chondroitin 4-sulfate release from stimulated platelets and its relation to thromboxane A2 formation and granule secretion.
(2008). The structure of glycosaminoglycans and their interactions with proteins.
(2002). Thrombin receptor antagonists; recent advances in PAR-1 antagonist development.